Recent Updates — CDT
CDT Equity Inc. filed a certificate of amendment with the Delaware Secretary of State to effectuate a 1-for-25 reverse stock split of its common stock, reducing outstanding shares from approximately 28 million to roughly 1,124,515. The transaction becomes effective on September 28, 2026, at 5:00 p.m. Eastern Time, with adjusted trading expected to commence on September 29, 2026. This action is taken to ensure continued compliance with Nasdaq's bid-price rule for listing maintenance. Fractional shares are not issued; instead, holders receive cash payments based on the closing price on the effective date. CDT Equity Inc. operates in the biopharmaceutical industry, focusing on data-driven drug discovery and therapeutic asset development.
On September 14, 2026, CDT Equity Inc. issued a senior secured convertible promissory note to J.J. Astor & Co. with a principal amount of $2,126,250 and net proceeds of $1,501,850. The note matures on March 1, 2027, requiring twenty-four weekly installments of $88,593.75. Concurrently, the company issued warrants to purchase 3,468,500 shares at an exercise price of $0.25 per share. Proceeds from the company's at-the-market offering program are prioritized to repay this note after satisfying a prior August note obligation. The lender may convert the debt into common stock at a conversion price equal to 70% of the lowest volume-weighted average price over the preceding twenty trading days, subject to a $0.05 floor and a 4.99% beneficial ownership limit. CDT Equity Inc. operates in the investment management industry.
CDT Equity Inc. amended its Securities Purchase Agreement with Sarborg Limited to acquire a 20% equity interest for $8,000,000. The amendment allows $1,750,000 of the consideration to be paid via common stock issuance and credits audit costs against the cash balance. CDT issued 650,000 shares to Sarborg on August 31, 2026, satisfying part of the equity portion. Remaining cash payments will come from at-the-market program proceeds, with minimum monthly payments of $150,000 and a final due date of May 31, 2027. Additionally, CDT issued a senior secured convertible promissory note to J.J. Astor & Co. for $541,620, receiving net proceeds of $375,002. The company also issued warrants to purchase 237,000 shares at an exercise price of $1.69 per share. The note was repaid in full on September 4, 2026, and no conversion shares were issued. CDT Equity Inc. operates as a holding company focused on investments in various industries.
CDT Equity Inc. appointed James Bligh as Chief Executive Officer effective August 31, 2026, with an annual base salary of $600,000 and a target bonus of 50% of base. Dr. Andrew Regan resigned as CEO and from the Board, receiving severance of $50,000 monthly for six months. The company's board size decreased to four members. At its August 28, 2026 annual meeting, shareholders approved a reverse stock split with a ratio between 1-for-2 and 1-for-100, authorized the issuance of shares under Nasdaq Listing Rule 5635 for senior secured convertible notes issued to J.J. Astor & Co., and approved the issuance of up to 12,131,770 shares upon exercise of pre-funded warrants. CDT Equity Inc. operates in the investment management industry.
CDT Equity Inc. entered into a Securities Purchase Agreement to acquire approximately 4.76% of Sarborg Limited by issuing pre-funded warrants exercisable for up to 12,131,770 shares at $0.0001 per share. The transaction involves existing investors in Sarborg, including CEO Andrew Regan’s Corvus Capital, which received warrants for 5,436,830 shares. Exercise of these warrants is contingent on stockholder approval to exceed Nasdaq’s 19.99% ownership limit and the filing of a resale registration statement within 60 days. Additionally, CDT Equity issued 123,537 common shares to service providers for services rendered. The company operates in the investment holding sector.